2-methyl-4-thiazolylmethyl diphenylphosphine oxide | 184246-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methyl-4-thiazolylmethyl diphenylphosphine oxide
• 英文别名: Thiazole, 4-[(diphenylphosphinyl)methyl]-2-methyl-；4-(diphenylphosphorylmethyl)-2-methyl-1,3-thiazole
• CAS: 184246-51-3
• 化学式: C₁₇H₁₆NOPS
• 分子量: 313.36
• InChiKey: RLNDTCUPCZWEQN-UHFFFAOYSA-N

物化性质

• 沸点：
  450.4±28.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-4-thiazolylmethyl diphenylphosphine oxide 在 吡啶 、 正丁基锂 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 13.5h， 生成 [(3Z,6S,7E)-3-iodo-7-methyl-8-(2-methyl-1,3-thiazol-4-yl)-6-triethylsilyloxyocta-3,7-dienyl] 2,2,2-trichloroethyl carbonate
  参考文献：
  名称：

  Probing the SAR of dEpoB via Chemical Synthesis:  A Total Synthesis Evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone B

  摘要：

  A practical total synthesis of 26-(1,3-dioxolanyl)-12,13-desoxyepothilone B (26-dioxolanyl dEpoB) was accomplished in a highly convergent manner. A novel sequence was developed to produce the vinyl iodide segment 17 in high enantiomeric excess, which was used in a key B-alkyl Suzuki merger. Subsequently, a Yamaguchi macrocyclization formed the core lactone, while a selective oxidation and a late stage Noyori acetalization incorporated the dioxolane functionality. Sufficient amounts of synthetic 26-dioxolane dEpoB were produced using this sequence for an in vivo analysis in mice containing xenograft CCRF-CEM tumors.

  DOI：

  10.1021/jo020180q
• 作为产物：
  描述：

  N-(1,3-dichloropropan-2-ylidene)ethanethioamide 在 四丁基碘化铵 、 caesium carbonate 、 zinc(II) chloride 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-methyl-4-thiazolylmethyl diphenylphosphine oxide
  参考文献：
  名称：

  En Route to a Plant Scale Synthesis of the Promising Antitumor Agent 12,13-Desoxyepothilone B

  摘要：

  [GRAPHICS]Efficient and processable syntheses of key building blocks of the antitumor agent 12,13-desoxyepothilone B (dEpoB) by catalytic asymmetric induction are herein described.

  DOI：

  10.1021/ol0059302
• 作为试剂：
  描述：

  2-methyl-4-thiazolylmethyl diphenylphosphine oxide 、 在 2-methyl-4-thiazolylmethyl diphenylphosphine oxide 作用下， 以18的产率得到
  参考文献：
  名称：

  Epothilone derivatives

  摘要：

  本发明涉及具有以下式的环丝菌素衍生物： 其中变量G，W，Q，X，Y，B1，B2，Z1，Z2和R1-R7在此定义，以及制备衍生物和其中间体的方法。

  公开号：

  US07125899B2

文献信息

• Synthesis of epothilones, intermediates thereto, analogues and uses thereof
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：US06369234B1

  公开（公告）日：2002-04-09

  The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype.

  本发明提供了用于制备依托酮A和B、去氧依托酮A和B及其类似物的汇聚过程。还提供了与依托酮A和B相关的类似物以及用于制备它们的中间体。本发明还提供了基于依托酮类似物的新型组合物，以及用于治疗癌症和发展出多药耐药表型的癌症的方法。
• A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio- and Stereoselective Synthesis of Lactam Analogues of the Epothilone Natural Products
  作者：Robert M. Borzilleri、Xiaoping Zheng、Robert J. Schmidt、James A. Johnson、Soong-Hoon Kim、John D. DiMarco、Craig R. Fairchild、Jack Z. Gougoutas、Francis Y. F. Lee、Byron H. Long、Gregory D. Vite

  DOI：10.1021/ja001899n

  日期：2000.9.1

  Several lactam analogues of the epothilones were prepared using a concise semisynthetic approach starting with the unprotected natural products. Highlighted in this strategy is a novel regio- and stereoselective Pd(0)-catalyzed azidation reaction of a macrocyclic lactone. Subsequent reduction and macrolactamization of the resulting azide acid intermediates provided the desired macrolactams in satisfactory

  从未受保护的天然产物开始，使用简洁的半合成方法制备了埃坡霉素的几种内酰胺类似物。该策略中的重点是大环内酯的新型区域选择性和立体选择性 Pd(0) 催化叠氮化反应。所得叠氮酸中间体的随后还原和大环内酰胺化以令人满意的总产率提供了所需的大环内酰胺。整个三步序列被简化为埃坡霉素 B-内酰胺 BMS-247550 的“一锅”工艺，目前正在进行 I 期临床试验。完成了制备埃坡霉素 C 的内酰胺类似物的初始全合成路线，并与更直接的半合成方法进行了比较。所有内酰胺类似物都在体外进行了评估，并讨论了结果。
• 14-Methyl-epothilones
  申请人：——

  公开号：US20030134883A1

  公开（公告）日：2003-07-17

  The present invention provides 14-methyl epothilone compounds, along with intermediates thereto, methods for their preparation, compositions comprising the compounds, and methods for their use in the treatment of cancer and other diseases and conditions characterized by undesired cellular hyperproliferation.

  本发明提供了14-甲基依托酮化合物，以及其中间体，其制备方法，包含该化合物的组合物，以及在治疗癌症和其他由不良细胞过度增殖特征的疾病和病况中使用的方法。
• EPOTHILONE DERIVATIVES
  申请人：Vite D. Gregory

  公开号：US20070255055A1

  公开（公告）日：2007-11-01

  The present invention relates to compounds of the formula Q is selected from the group consisting of G is selected from the group consisting of alkyl, substituted alkyl, substituted or unsubstituted aryl, heterocyclo, W is O or NR 15 ; X is O or H,H; Y is selected from the group consisting of O; H,OR 16 ; OR 17 ,OR 17 ; NOR 18 ; H,NOR 19 ; H,NR 20 R 21 ; H,H; or CHR 22 ; OR 17 OR 17 can be a cyclic ketal; Z 1 and Z 2 are selected from the group consisting of CH 2 , O, NR 23 , S, or SO 2 , wherein only one of Z and Z 2 is a heteroatom; B 1 and B 2 are selected from the group consisting of OR 24 , or OCOR 25 , or O 2 CNR 26 R 27 ; when B 1 is H and Y is OH, H they can form a six-membered ring ketal or acetal; D is selected from the group consisting of NR 28 R 29 , NR 30 COR 31 or saturated heterocycle; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 18 , R 19 , R 20 , R 21 , R 22 , R 26 , and R 27 are selected from the group H, alkyl, substituted alkyl, or aryl and when R 1 and R 2 are alkyl can be joined to form a cycloalkyl; R 3 and R 4 are alkyl can be joined to form a cycloalkyl; R 9 , R 10 , R 16 , R 17 , R 24 , R 25 , and R 31 are selected from the group H, alkyl, or substituted alkyl; R 8 , R 11 , R 12 , R 28 , R 30 , R 32 , R 33 , and R 30 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; R 15 , R 23 and R 29 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R 32 C═O, R 33 SO 2 , hydroxy, O-alkyl or O-substituted alkyl, the pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein W and X are both O; and R 1 , R 2 , R 7 , are H; and R 3 , R 4 , R 6 , are methyl; and R 8 , is H or methyl; and Z 1 , and Z 2 , are CH 2 ; and G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above are excluded.

  本发明涉及以下化合物的公式：其中Q选自G选自烷基，取代烷基，取代或未取代芳基，杂环烷基，W为O或NR15；X为O或H；Y选自O，H，OR16，OR17，NOR18，H，NOR19，H，NR20R21，H，H或CHR22；OR17OR17可以是环状缩酮；Z1和Z2选自CH2，O，NR23，S或SO2，其中仅Z和Z2中的一个为杂原子；B1和B2选自OR24，或OCOR25，或O2CNR26R27；当B1为H且Y为OH时，它们可以形成六元环缩酮或缩醛；D选自NR28R29，NR30COR31或饱和杂环；R1，R2，R3，R4，R5，R6，R7，R13，R14，R18，R19，R20，R21，R22，R26和R27选自H，烷基，取代烷基或芳基，当R1和R2为烷基时，可以连接成环烷基；R3和R4为烷基时，可以连接成环烷基；R9，R10，R16，R17，R24，R25和R31选自H，烷基或取代烷基；R8，R11，R12，R28，R30，R32，R33和R30选自H，烷基，取代烷基，芳基，取代芳基，环烷基或杂环烷基；R15，R23和R29选自H，烷基，取代烷基，芳基，取代芳基，环烷基，杂环烷基，R32C═O，R33SO2，羟基，O-烷基或O-取代烷基，其药学上可接受的盐和任何水合物，溶剂化合物或其几何，光学和立体异构体，但其中W和X都是O；并且R1，R2，R7为H；并且R3，R4，R6为甲基；并且R8为H或甲基；并且Z1和Z2为CH2；并且G为1-甲基-2-（取代-4-噻唑基）乙烯基；并且Q如上所定义被排除在外。
• Synthesis of synthons for the manufacture of bioactive compounds
  申请人：Wong Chi-Huey

  公开号：US20070015260A1

  公开（公告）日：2007-01-18

  The present invention is based on the discovery that 2-deoxyribose-5-phosphate aldolase (DERA, EC 4.1.2.4) and variants thereof can be used to catalyze sequential asymmetric aldol reactions between a wide variety of donor and acceptor aldehydes. The reaction products typically contain at least two new stereogenic centers and can be produced in enantiomerically pure form. As such, DERA catalyzed asymmetric aldol chemistry can be exploited to produce synthons for the synthesis of a variety of bioactive molecules.

  本发明基于发现，2-去氧核糖-5-磷酸醛基酶（DERA，EC 4.1.2.4）及其变体可用于催化多种供体和受体醛之间的顺序不对称醛基反应。反应产物通常包含至少两个新的立体异构中心，并可以对映纯形式制备。因此，DERA催化的不对称醛基化学可用于生产用于合成各种生物活性分子的合成子。